Global Antibody-drug Conjugates Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Antibody-drug Conjugates market size was valued at US$ 15928 million in 2025 and is forecast to a readjusted size of US$ 39647 million by 2032 with a CAGR of 13.9% during review period.
Antibody-drug Conjugates are targeted biopharmaceuticals that combine a monoclonal antibody with a cytotoxic or biologically active payload through a chemical linker. The antibody recognizes a tumor-associated antigen, enabling selective internalization or localized payload release while reducing systemic exposure relative to conventional chemotherapy. Core product attributes include antigen specificity, antibody format, linker stability and cleavage mechanism, payload class and potency, drug-to-antibody ratio, conjugation-site distribution, aggregation level, formulation stability and dosing strength. Commercial products are primarily supplied as intravenous liquid or lyophilized injections for solid tumors and hematologic malignancies. This study focuses on commercial Antibody-drug Conjugates and evaluates the market by payload mechanism, linker type, conjugation technology, target antigen, therapeutic indication and geographic market. Market value is measured primarily through manufacturer-recognized net product sales because vial strengths, body-weight-based dosing, treatment cycles, regional reimbursement and alliance accounting differ materially between products.
Value creation is concentrated in target validation, proprietary linker-payload chemistry, reproducible conjugation, clinical differentiation, regulatory execution and commercial access. Downstream products are distributed through oncology hospitals, specialist treatment centers, authorized pharmaceutical distributors and specialty channels, with payment influenced by indication, patient weight, treatment cycle, vial strength, reimbursement and negotiated discounts. Commercial ADCs can support high product-level gross margins, but development failures, pharmacovigilance, diagnostic support and post-approval trials consume substantial lifecycle investment. Supply reliability and capacity planning therefore remain important competitive factors alongside clinical performance.
Conventional stochastic conjugation remains widely used in marketed products because of established manufacturing experience and regulatory familiarity. However, site-specific and controlled conjugation technologies are attracting greater development investment because they can narrow drug-to-antibody ratio distribution and improve batch consistency. Solid tumors represent the largest application segment, led by breast, urothelial, lung, gynecologic and gastrointestinal cancers. Hematologic malignancies remain an important established segment, especially where validated lineage antigens support efficient internalization and clear patient selection.
Asia-Pacific is developing into the most dynamic regional opportunity. Japan combines established ADC innovation with advanced oncology infrastructure, while China is expanding domestic development, manufacturing capacity, regulatory approvals and commercial partnerships. Chinese products are also increasing licensing activity in international markets, strengthening the region’s role in global innovation rather than only local supply. Other emerging markets offer longer-term demand potential, but access remains constrained by oncology budgets, diagnostic availability, specialist capacity and cold-chain distribution.
Global Antibody-drug Conjugates market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Antibody-drug Conjugates market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Antibody-drug Conjugates market shares of main players, in revenue ($ Million), 2021-2026
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Antibody-drug Conjugates market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Chapter 2, to profile the top players of Antibody-drug Conjugates, with revenue, gross margin, and global market share of Antibody-drug Conjugates from 2021 to 2026.
Chapter 3, the Antibody-drug Conjugates competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Antibody-drug Conjugates market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antibody-drug Conjugates.
Chapter 13, to describe Antibody-drug Conjugates research findings and conclusion.
Antibody-drug Conjugates are targeted biopharmaceuticals that combine a monoclonal antibody with a cytotoxic or biologically active payload through a chemical linker. The antibody recognizes a tumor-associated antigen, enabling selective internalization or localized payload release while reducing systemic exposure relative to conventional chemotherapy. Core product attributes include antigen specificity, antibody format, linker stability and cleavage mechanism, payload class and potency, drug-to-antibody ratio, conjugation-site distribution, aggregation level, formulation stability and dosing strength. Commercial products are primarily supplied as intravenous liquid or lyophilized injections for solid tumors and hematologic malignancies. This study focuses on commercial Antibody-drug Conjugates and evaluates the market by payload mechanism, linker type, conjugation technology, target antigen, therapeutic indication and geographic market. Market value is measured primarily through manufacturer-recognized net product sales because vial strengths, body-weight-based dosing, treatment cycles, regional reimbursement and alliance accounting differ materially between products.
Key Findings
- Global Antibody-drug Conjugate shipments reached approximately 6.0 million standard vial equivalents in 2025
- The weighted average manufacturer selling price was approximately USD 2,580 per standard vial equivalent in 2025
- More than 15 Antibody-drug Conjugates had entered commercial use across major markets by 2025
- North America remains the largest regional market supported by rapid launch uptake and premium oncology reimbursement
- Solid tumors have become the principal demand base while hematologic malignancies retain established clinical positions
- Topoisomerase I inhibitor payloads and cleavable linkers are driving the fastest product expansion
Market Trends
Antibody-drug Conjugates are evolving from relatively heterogeneous first-generation products toward more stable, homogeneous and therapeutically differentiated platforms. Development priorities are shifting from late-line hematologic indications to larger solid-tumor populations, earlier treatment lines and biomarker-defined pan-tumor opportunities. New products increasingly use highly potent topoisomerase I inhibitors, optimized cleavable linkers and controlled drug-to-antibody ratios to strengthen bystander activity while managing systemic toxicity. Site-specific conjugation, biparatopic or bispecific antibodies, dual-payload architectures and immune-stimulating payloads represent the next layer of product innovation, although their manufacturing and regulatory requirements remain demanding. At the clinical level, combination regimens with immune checkpoint inhibitors and other targeted therapies are expanding the addressable population. Companion diagnostics, quantitative antigen testing and resistance monitoring are consequently becoming more important to patient selection, treatment sequencing and lifecycle management.Market Dynamics
Drivers
Market expansion is being driven by the broadening of approved indications, movement into earlier treatment lines and continued validation of ADCs in major solid tumors. Successful products have demonstrated that an effective antibody, linker and payload combination can improve clinical outcomes in patients with limited alternatives, supporting physician adoption and premium oncology pricing. Pharmaceutical companies are increasing internal development, licensing and co-development investment because a validated ADC platform can generate multiple target-specific candidates. Growth is also reinforced by improved biomarker testing, expansion of oncology treatment infrastructure and increasing regulatory acceptance of ADCs across North America, Europe and Asia.Restraints
ADC development and production involve substantially greater complexity than conventional monoclonal antibodies. Manufacturers must coordinate antibody production, high-potency payload synthesis, linker chemistry, conjugation, purification, aseptic filling and specialized analytical testing under tightly controlled conditions. Payload containment requirements, limited qualified capacity, long production lead times and low initial batch volumes increase unit costs. Commercial adoption may also be constrained by treatment-related toxicities, dose interruptions, regional reimbursement negotiations and the need for specialized infusion and adverse-event management. These factors can delay penetration even after regulatory approval.Opportunities
The most attractive opportunities are emerging from new tumor targets, improved therapeutic windows and expansion beyond heavily pretreated patients. Targets such as B7-H3, HER3, CLDN18.2, c-MET and other tumor-associated antigens offer room for differentiated products, particularly where existing therapies provide limited durability. Further opportunities exist in earlier-stage disease, perioperative treatment, biomarker-defined pan-tumor indications and rational combinations with immunotherapy. Asia-Pacific offers additional potential through local clinical development, regional licensing, domestic manufacturing and broader reimbursement access. Platform suppliers and specialized contract manufacturers can also benefit as developers seek external capacity for payload production, conjugation and high-potency fill-finish operations.Challenges
The principal challenge is maintaining a sufficiently wide therapeutic index while preserving strong antitumor activity. Antigen heterogeneity, variable internalization, payload resistance, linker instability and off-target toxicity can weaken clinical differentiation or limit dose intensity. Developers must also demonstrate superiority against rapidly changing standards of care, requiring larger and more expensive comparative trials. Intellectual-property overlap across antibodies, linkers, payloads and conjugation methods increases freedom-to-operate risk. Commercially, companies face indication crowding, pricing scrutiny and the possibility that competing ADCs, bispecific antibodies, radioligand therapies or other targeted modalities will reduce the value of late-entry products.Industry Chain Analysis
The upstream ADC industry chain comprises monoclonal antibody cell lines and biologic drug substance, linker intermediates, highly potent payloads, conjugation reagents, chromatography resins, single-use processing systems and analytical materials. Payload and linker production require advanced organic synthesis, containment and impurity control, while antibody production relies on mature mammalian-cell bioprocessing. Midstream activities integrate antibody manufacture with conjugation, purification, formulation, sterile filling, quality testing and cold-chain release. Process consistency is critical because changes in drug-to-antibody ratio, free payload, aggregation or conjugation-site distribution can materially affect efficacy, safety and shelf life.Value creation is concentrated in target validation, proprietary linker-payload chemistry, reproducible conjugation, clinical differentiation, regulatory execution and commercial access. Downstream products are distributed through oncology hospitals, specialist treatment centers, authorized pharmaceutical distributors and specialty channels, with payment influenced by indication, patient weight, treatment cycle, vial strength, reimbursement and negotiated discounts. Commercial ADCs can support high product-level gross margins, but development failures, pharmacovigilance, diagnostic support and post-approval trials consume substantial lifecycle investment. Supply reliability and capacity planning therefore remain important competitive factors alongside clinical performance.
Segment Insights
By payload mechanism, microtubule inhibitors retain a substantial installed commercial base through established products, while topoisomerase I inhibitors are gaining strategic importance because of their activity in solid tumors and potential bystander effect. DNA-damaging payloads remain important in selected hematologic indications but represent a narrower commercial segment. Cleavable linkers increasingly dominate newer product development because they facilitate intracellular or tumor-microenvironment payload release, whereas non-cleavable linkers retain relevance where plasma stability and controlled intracellular processing are prioritized.Conventional stochastic conjugation remains widely used in marketed products because of established manufacturing experience and regulatory familiarity. However, site-specific and controlled conjugation technologies are attracting greater development investment because they can narrow drug-to-antibody ratio distribution and improve batch consistency. Solid tumors represent the largest application segment, led by breast, urothelial, lung, gynecologic and gastrointestinal cancers. Hematologic malignancies remain an important established segment, especially where validated lineage antigens support efficient internalization and clear patient selection.
Downstream Market Opportunities
The largest downstream opportunity lies in expanding ADCs from salvage therapy into earlier treatment lines and curative-intent settings. Breast cancer remains a major commercial foundation, while urothelial, lung, ovarian, cervical, gastric and other biomarker-defined solid tumors are creating additional demand. Treatment centers increasingly require integrated diagnostic testing, standardized toxicity-management pathways and dependable product availability rather than drug supply alone. Opportunities are also emerging from community oncology adoption, combination regimens and broader testing of low or heterogeneous antigen expression. Products that demonstrate clinically meaningful survival benefits, manageable adverse events and practical dosing schedules are better positioned to secure formulary access and sustained physician use.Regional Insights
North America remains the largest Antibody-drug Conjugates market because the United States combines early regulatory launches, concentrated oncology expertise, broad biomarker testing and relatively high net drug prices. Commercial uptake can be rapid when an ADC receives a differentiated label or moves into an earlier treatment line, although payer controls and indication-specific reimbursement are becoming more influential. Europe represents a major but more price-controlled market, with country-level health technology assessment, reimbursement timing and treatment guidelines producing uneven launch curves.Asia-Pacific is developing into the most dynamic regional opportunity. Japan combines established ADC innovation with advanced oncology infrastructure, while China is expanding domestic development, manufacturing capacity, regulatory approvals and commercial partnerships. Chinese products are also increasing licensing activity in international markets, strengthening the region’s role in global innovation rather than only local supply. Other emerging markets offer longer-term demand potential, but access remains constrained by oncology budgets, diagnostic availability, specialist capacity and cold-chain distribution.
Competitive Landscape Analysis
Competition is shifting from a small group of early ADC pioneers toward integrated global pharmaceutical portfolios and specialized platform companies. Daiichi Sankyo and AstraZeneca have established a strong position around the DXd platform, while Roche retains an important commercial franchise across solid tumors and hematologic malignancies. Pfizer’s acquisition of Seagen consolidated Padcev, Adcetris and Tivdak within a larger oncology organization, and AbbVie’s acquisition of ImmunoGen brought Elahere and related technology into its portfolio. Gilead, Astellas, GSK, Takeda and ADC Therapeutics compete through marketed products, partnerships or indication expansion. In China, RemeGen and Kelun-Biotech have entered commercial-stage competition, while Hengrui, Hansoh, CSPC, Mabwell, Duality Biologics, MediLink Therapeutics and other developers are advancing differentiated targets and linker-payload platforms. Future leadership will depend less on the number of pipeline candidates and more on clinical differentiation, manufacturing reproducibility, biomarker strategy, global regulatory execution, market access and the ability to manage combination development across multiple indications.Report Scope
This report is a detailed and comprehensive analysis for global Antibody-drug Conjugates market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.Key Features:
Global Antibody-drug Conjugates market size and forecasts, in consumption value ($ Million), 2021-2032Global Antibody-drug Conjugates market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Antibody-drug Conjugates market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Antibody-drug Conjugates market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Antibody-drug Conjugates
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Antibody-drug Conjugates market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Market segment by Type
- HER2-Directed ADCs
- TROP2-Directed ADCs
- Hematologic-Lineage Antigen ADCs
- Other Target Antigen ADCs
Market segment by Payload Mechanism
- Topoisomerase I Inhibitor ADCs
- Microtubule Inhibitor ADCs
- DNA-Damaging ADCs
- Other Payload ADCs
Market segment by Drug-To-Antibody Ratio
- DAR Up To 4
- DAR Above 4 And Below 8
- DAR 8 And Above
- Other
Market segment by Application
- Breast and Gynecologic Malignancies
- Lung and Other Thoracic Malignancies
- Other Solid Tumors
- Hematologic Malignancies
Market segment by players, this report covers
- Daiichi Sankyo Company, Limited
- Roche
- Pfizer Inc.
- Gilead Sciences, Inc.
- Astellas Pharma Inc.
- AbbVie Inc.
- GSK plc
- ADC Therapeutics SA
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
- Genmab A/S
- Johnson & Johnson
- Merck & Co., Inc.
- MacroGenics, Inc.
- Sutro Biopharma, Inc.
- Heidelberg Pharma AG
- RemeGen Co., Ltd.
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Innovent Biologics, Inc.
- CSPC Pharmaceutical Group Limited
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Lepu Biopharma Co., Ltd.
- Duality Biologics (Shanghai) Co., Ltd.
- MediLink Therapeutics (Suzhou) Co., Ltd.
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
- Hangzhou DAC Biotechnology Co., Ltd.
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
- Sichuan Biokin Pharmaceutical Co., Ltd.
- Bio-Thera Solutions, Ltd.
Market segment by regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
- South America (Brazil, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Antibody-drug Conjugates product scope, market overview, market estimation caveats and base year.Chapter 2, to profile the top players of Antibody-drug Conjugates, with revenue, gross margin, and global market share of Antibody-drug Conjugates from 2021 to 2026.
Chapter 3, the Antibody-drug Conjugates competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Antibody-drug Conjugates market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antibody-drug Conjugates.
Chapter 13, to describe Antibody-drug Conjugates research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Antibody-drug Conjugates by Type
1.3.1 Overview: Global Antibody-drug Conjugates Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Antibody-drug Conjugates Consumption Value Market Share by Type in 2025
1.3.3 HER2-Directed ADCs
1.3.4 TROP2-Directed ADCs
1.3.5 Hematologic-Lineage Antigen ADCs
1.3.6 Other Target Antigen ADCs
1.4 Classification of Antibody-drug Conjugates by Payload Mechanism
1.4.1 Overview: Global Antibody-drug Conjugates Market Size by Payload Mechanism: 2021 Versus 2025 Versus 2032
1.4.2 Global Antibody-drug Conjugates Consumption Value Market Share by Payload Mechanism in 2025
1.4.3 Topoisomerase I Inhibitor ADCs
1.4.4 Microtubule Inhibitor ADCs
1.4.5 DNA-Damaging ADCs
1.4.6 Other Payload ADCs
1.5 Classification of Antibody-drug Conjugates by Drug-To-Antibody Ratio
1.5.1 Overview: Global Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio: 2021 Versus 2025 Versus 2032
1.5.2 Global Antibody-drug Conjugates Consumption Value Market Share by Drug-To-Antibody Ratio in 2025
1.5.3 DAR Up To 4
1.5.4 DAR Above 4 And Below 8
1.5.5 DAR 8 And Above
1.5.6 Other
1.6 Global Antibody-drug Conjugates Market by Application
1.6.1 Overview: Global Antibody-drug Conjugates Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Breast and Gynecologic Malignancies
1.6.3 Lung and Other Thoracic Malignancies
1.6.4 Other Solid Tumors
1.6.5 Hematologic Malignancies
1.7 Global Antibody-drug Conjugates Market Size & Forecast
1.8 Global Antibody-drug Conjugates Market Size and Forecast by Region
1.8.1 Global Antibody-drug Conjugates Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Antibody-drug Conjugates Market Size by Region, (2021-2032)
1.8.3 North America Antibody-drug Conjugates Market Size and Prospect (2021-2032)
1.8.4 Europe Antibody-drug Conjugates Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Antibody-drug Conjugates Market Size and Prospect (2021-2032)
1.8.6 South America Antibody-drug Conjugates Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Antibody-drug Conjugates Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Daiichi Sankyo Company, Limited
2.1.1 Daiichi Sankyo Company, Limited Details
2.1.2 Daiichi Sankyo Company, Limited Major Business
2.1.3 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product and Solutions
2.1.4 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Daiichi Sankyo Company, Limited Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Antibody-drug Conjugates Product and Solutions
2.2.4 Roche Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Roche Recent Developments and Future Plans
2.3 Pfizer Inc.
2.3.1 Pfizer Inc. Details
2.3.2 Pfizer Inc. Major Business
2.3.3 Pfizer Inc. Antibody-drug Conjugates Product and Solutions
2.3.4 Pfizer Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Pfizer Inc. Recent Developments and Future Plans
2.4 Gilead Sciences, Inc.
2.4.1 Gilead Sciences, Inc. Details
2.4.2 Gilead Sciences, Inc. Major Business
2.4.3 Gilead Sciences, Inc. Antibody-drug Conjugates Product and Solutions
2.4.4 Gilead Sciences, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Gilead Sciences, Inc. Recent Developments and Future Plans
2.5 Astellas Pharma Inc.
2.5.1 Astellas Pharma Inc. Details
2.5.2 Astellas Pharma Inc. Major Business
2.5.3 Astellas Pharma Inc. Antibody-drug Conjugates Product and Solutions
2.5.4 Astellas Pharma Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Astellas Pharma Inc. Recent Developments and Future Plans
2.6 AbbVie Inc.
2.6.1 AbbVie Inc. Details
2.6.2 AbbVie Inc. Major Business
2.6.3 AbbVie Inc. Antibody-drug Conjugates Product and Solutions
2.6.4 AbbVie Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 AbbVie Inc. Recent Developments and Future Plans
2.7 GSK plc
2.7.1 GSK plc Details
2.7.2 GSK plc Major Business
2.7.3 GSK plc Antibody-drug Conjugates Product and Solutions
2.7.4 GSK plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 GSK plc Recent Developments and Future Plans
2.8 ADC Therapeutics SA
2.8.1 ADC Therapeutics SA Details
2.8.2 ADC Therapeutics SA Major Business
2.8.3 ADC Therapeutics SA Antibody-drug Conjugates Product and Solutions
2.8.4 ADC Therapeutics SA Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 ADC Therapeutics SA Recent Developments and Future Plans
2.9 Takeda Pharmaceutical Company Limited
2.9.1 Takeda Pharmaceutical Company Limited Details
2.9.2 Takeda Pharmaceutical Company Limited Major Business
2.9.3 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product and Solutions
2.9.4 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
2.10 AstraZeneca plc
2.10.1 AstraZeneca plc Details
2.10.2 AstraZeneca plc Major Business
2.10.3 AstraZeneca plc Antibody-drug Conjugates Product and Solutions
2.10.4 AstraZeneca plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 AstraZeneca plc Recent Developments and Future Plans
2.11 Genmab A/S
2.11.1 Genmab A/S Details
2.11.2 Genmab A/S Major Business
2.11.3 Genmab A/S Antibody-drug Conjugates Product and Solutions
2.11.4 Genmab A/S Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Genmab A/S Recent Developments and Future Plans
2.12 Johnson & Johnson
2.12.1 Johnson & Johnson Details
2.12.2 Johnson & Johnson Major Business
2.12.3 Johnson & Johnson Antibody-drug Conjugates Product and Solutions
2.12.4 Johnson & Johnson Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Johnson & Johnson Recent Developments and Future Plans
2.13 Merck & Co., Inc.
2.13.1 Merck & Co., Inc. Details
2.13.2 Merck & Co., Inc. Major Business
2.13.3 Merck & Co., Inc. Antibody-drug Conjugates Product and Solutions
2.13.4 Merck & Co., Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Merck & Co., Inc. Recent Developments and Future Plans
2.14 MacroGenics, Inc.
2.14.1 MacroGenics, Inc. Details
2.14.2 MacroGenics, Inc. Major Business
2.14.3 MacroGenics, Inc. Antibody-drug Conjugates Product and Solutions
2.14.4 MacroGenics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 MacroGenics, Inc. Recent Developments and Future Plans
2.15 Sutro Biopharma, Inc.
2.15.1 Sutro Biopharma, Inc. Details
2.15.2 Sutro Biopharma, Inc. Major Business
2.15.3 Sutro Biopharma, Inc. Antibody-drug Conjugates Product and Solutions
2.15.4 Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Sutro Biopharma, Inc. Recent Developments and Future Plans
2.16 Heidelberg Pharma AG
2.16.1 Heidelberg Pharma AG Details
2.16.2 Heidelberg Pharma AG Major Business
2.16.3 Heidelberg Pharma AG Antibody-drug Conjugates Product and Solutions
2.16.4 Heidelberg Pharma AG Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Heidelberg Pharma AG Recent Developments and Future Plans
2.17 RemeGen Co., Ltd.
2.17.1 RemeGen Co., Ltd. Details
2.17.2 RemeGen Co., Ltd. Major Business
2.17.3 RemeGen Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.17.4 RemeGen Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 RemeGen Co., Ltd. Recent Developments and Future Plans
2.18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2.18.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details
2.18.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
2.18.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.18.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments and Future Plans
2.19 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
2.19.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details
2.19.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
2.19.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.19.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments and Future Plans
2.20 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
2.20.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Details
2.20.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Major Business
2.20.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.20.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments and Future Plans
2.21 Innovent Biologics, Inc.
2.21.1 Innovent Biologics, Inc. Details
2.21.2 Innovent Biologics, Inc. Major Business
2.21.3 Innovent Biologics, Inc. Antibody-drug Conjugates Product and Solutions
2.21.4 Innovent Biologics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 Innovent Biologics, Inc. Recent Developments and Future Plans
2.22 CSPC Pharmaceutical Group Limited
2.22.1 CSPC Pharmaceutical Group Limited Details
2.22.2 CSPC Pharmaceutical Group Limited Major Business
2.22.3 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product and Solutions
2.22.4 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 CSPC Pharmaceutical Group Limited Recent Developments and Future Plans
2.23 Mabwell (Shanghai) Bioscience Co., Ltd.
2.23.1 Mabwell (Shanghai) Bioscience Co., Ltd. Details
2.23.2 Mabwell (Shanghai) Bioscience Co., Ltd. Major Business
2.23.3 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.23.4 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.23.5 Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments and Future Plans
2.24 Lepu Biopharma Co., Ltd.
2.24.1 Lepu Biopharma Co., Ltd. Details
2.24.2 Lepu Biopharma Co., Ltd. Major Business
2.24.3 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.24.4 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.24.5 Lepu Biopharma Co., Ltd. Recent Developments and Future Plans
2.25 Duality Biologics (Shanghai) Co., Ltd.
2.25.1 Duality Biologics (Shanghai) Co., Ltd. Details
2.25.2 Duality Biologics (Shanghai) Co., Ltd. Major Business
2.25.3 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.25.4 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.25.5 Duality Biologics (Shanghai) Co., Ltd. Recent Developments and Future Plans
2.26 MediLink Therapeutics (Suzhou) Co., Ltd.
2.26.1 MediLink Therapeutics (Suzhou) Co., Ltd. Details
2.26.2 MediLink Therapeutics (Suzhou) Co., Ltd. Major Business
2.26.3 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.26.4 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.26.5 MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments and Future Plans
2.27 GeneQuantum Healthcare (Suzhou) Co., Ltd.
2.27.1 GeneQuantum Healthcare (Suzhou) Co., Ltd. Details
2.27.2 GeneQuantum Healthcare (Suzhou) Co., Ltd. Major Business
2.27.3 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.27.4 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.27.5 GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments and Future Plans
2.28 Hangzhou DAC Biotechnology Co., Ltd.
2.28.1 Hangzhou DAC Biotechnology Co., Ltd. Details
2.28.2 Hangzhou DAC Biotechnology Co., Ltd. Major Business
2.28.3 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.28.4 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.28.5 Hangzhou DAC Biotechnology Co., Ltd. Recent Developments and Future Plans
2.29 Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
2.29.1 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Details
2.29.2 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Major Business
2.29.3 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.29.4 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.29.5 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments and Future Plans
2.30 Sichuan Biokin Pharmaceutical Co., Ltd.
2.30.1 Sichuan Biokin Pharmaceutical Co., Ltd. Details
2.30.2 Sichuan Biokin Pharmaceutical Co., Ltd. Major Business
2.30.3 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.30.4 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.30.5 Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments and Future Plans
2.31 Bio-Thera Solutions, Ltd.
2.31.1 Bio-Thera Solutions, Ltd. Details
2.31.2 Bio-Thera Solutions, Ltd. Major Business
2.31.3 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product and Solutions
2.31.4 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.31.5 Bio-Thera Solutions, Ltd. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antibody-drug Conjugates Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Antibody-drug Conjugates by Company Revenue
3.2.2 Top 3 Antibody-drug Conjugates Players Market Share in 2025
3.2.3 Top 6 Antibody-drug Conjugates Players Market Share in 2025
3.3 Antibody-drug Conjugates Market: Overall Company Footprint Analysis
3.3.1 Antibody-drug Conjugates Market: Region Footprint
3.3.2 Antibody-drug Conjugates Market: Company Product Type Footprint
3.3.3 Antibody-drug Conjugates Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Antibody-drug Conjugates Consumption Value and Market Share by Type (2021-2026)
4.2 Global Antibody-drug Conjugates Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2026)
5.2 Global Antibody-drug Conjugates Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Antibody-drug Conjugates Consumption Value by Type (2021-2032)
6.2 North America Antibody-drug Conjugates Market Size by Application (2021-2032)
6.3 North America Antibody-drug Conjugates Market Size by Country
6.3.1 North America Antibody-drug Conjugates Consumption Value by Country (2021-2032)
6.3.2 United States Antibody-drug Conjugates Market Size and Forecast (2021-2032)
6.3.3 Canada Antibody-drug Conjugates Market Size and Forecast (2021-2032)
6.3.4 Mexico Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Antibody-drug Conjugates Consumption Value by Type (2021-2032)
7.2 Europe Antibody-drug Conjugates Consumption Value by Application (2021-2032)
7.3 Europe Antibody-drug Conjugates Market Size by Country
7.3.1 Europe Antibody-drug Conjugates Consumption Value by Country (2021-2032)
7.3.2 Germany Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7.3.3 France Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7.3.5 Russia Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7.3.6 Italy Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Antibody-drug Conjugates Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Antibody-drug Conjugates Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Antibody-drug Conjugates Market Size by Region
8.3.1 Asia-Pacific Antibody-drug Conjugates Consumption Value by Region (2021-2032)
8.3.2 China Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.3 Japan Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.4 South Korea Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.5 India Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.7 Australia Antibody-drug Conjugates Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Antibody-drug Conjugates Consumption Value by Type (2021-2032)
9.2 South America Antibody-drug Conjugates Consumption Value by Application (2021-2032)
9.3 South America Antibody-drug Conjugates Market Size by Country
9.3.1 South America Antibody-drug Conjugates Consumption Value by Country (2021-2032)
9.3.2 Brazil Antibody-drug Conjugates Market Size and Forecast (2021-2032)
9.3.3 Argentina Antibody-drug Conjugates Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Antibody-drug Conjugates Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Antibody-drug Conjugates Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Antibody-drug Conjugates Market Size by Country
10.3.1 Middle East & Africa Antibody-drug Conjugates Consumption Value by Country (2021-2032)
10.3.2 Turkey Antibody-drug Conjugates Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Antibody-drug Conjugates Market Size and Forecast (2021-2032)
10.3.4 UAE Antibody-drug Conjugates Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Antibody-drug Conjugates Market Drivers
11.2 Antibody-drug Conjugates Market Restraints
11.3 Antibody-drug Conjugates Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Antibody-drug Conjugates Industry Chain
12.2 Antibody-drug Conjugates Upstream Analysis
12.3 Antibody-drug Conjugates Midstream Analysis
12.4 Antibody-drug Conjugates Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Antibody-drug Conjugates by Type
1.3.1 Overview: Global Antibody-drug Conjugates Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Antibody-drug Conjugates Consumption Value Market Share by Type in 2025
1.3.3 HER2-Directed ADCs
1.3.4 TROP2-Directed ADCs
1.3.5 Hematologic-Lineage Antigen ADCs
1.3.6 Other Target Antigen ADCs
1.4 Classification of Antibody-drug Conjugates by Payload Mechanism
1.4.1 Overview: Global Antibody-drug Conjugates Market Size by Payload Mechanism: 2021 Versus 2025 Versus 2032
1.4.2 Global Antibody-drug Conjugates Consumption Value Market Share by Payload Mechanism in 2025
1.4.3 Topoisomerase I Inhibitor ADCs
1.4.4 Microtubule Inhibitor ADCs
1.4.5 DNA-Damaging ADCs
1.4.6 Other Payload ADCs
1.5 Classification of Antibody-drug Conjugates by Drug-To-Antibody Ratio
1.5.1 Overview: Global Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio: 2021 Versus 2025 Versus 2032
1.5.2 Global Antibody-drug Conjugates Consumption Value Market Share by Drug-To-Antibody Ratio in 2025
1.5.3 DAR Up To 4
1.5.4 DAR Above 4 And Below 8
1.5.5 DAR 8 And Above
1.5.6 Other
1.6 Global Antibody-drug Conjugates Market by Application
1.6.1 Overview: Global Antibody-drug Conjugates Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Breast and Gynecologic Malignancies
1.6.3 Lung and Other Thoracic Malignancies
1.6.4 Other Solid Tumors
1.6.5 Hematologic Malignancies
1.7 Global Antibody-drug Conjugates Market Size & Forecast
1.8 Global Antibody-drug Conjugates Market Size and Forecast by Region
1.8.1 Global Antibody-drug Conjugates Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Antibody-drug Conjugates Market Size by Region, (2021-2032)
1.8.3 North America Antibody-drug Conjugates Market Size and Prospect (2021-2032)
1.8.4 Europe Antibody-drug Conjugates Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Antibody-drug Conjugates Market Size and Prospect (2021-2032)
1.8.6 South America Antibody-drug Conjugates Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Antibody-drug Conjugates Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Daiichi Sankyo Company, Limited
2.1.1 Daiichi Sankyo Company, Limited Details
2.1.2 Daiichi Sankyo Company, Limited Major Business
2.1.3 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product and Solutions
2.1.4 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Daiichi Sankyo Company, Limited Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Antibody-drug Conjugates Product and Solutions
2.2.4 Roche Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Roche Recent Developments and Future Plans
2.3 Pfizer Inc.
2.3.1 Pfizer Inc. Details
2.3.2 Pfizer Inc. Major Business
2.3.3 Pfizer Inc. Antibody-drug Conjugates Product and Solutions
2.3.4 Pfizer Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Pfizer Inc. Recent Developments and Future Plans
2.4 Gilead Sciences, Inc.
2.4.1 Gilead Sciences, Inc. Details
2.4.2 Gilead Sciences, Inc. Major Business
2.4.3 Gilead Sciences, Inc. Antibody-drug Conjugates Product and Solutions
2.4.4 Gilead Sciences, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Gilead Sciences, Inc. Recent Developments and Future Plans
2.5 Astellas Pharma Inc.
2.5.1 Astellas Pharma Inc. Details
2.5.2 Astellas Pharma Inc. Major Business
2.5.3 Astellas Pharma Inc. Antibody-drug Conjugates Product and Solutions
2.5.4 Astellas Pharma Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Astellas Pharma Inc. Recent Developments and Future Plans
2.6 AbbVie Inc.
2.6.1 AbbVie Inc. Details
2.6.2 AbbVie Inc. Major Business
2.6.3 AbbVie Inc. Antibody-drug Conjugates Product and Solutions
2.6.4 AbbVie Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 AbbVie Inc. Recent Developments and Future Plans
2.7 GSK plc
2.7.1 GSK plc Details
2.7.2 GSK plc Major Business
2.7.3 GSK plc Antibody-drug Conjugates Product and Solutions
2.7.4 GSK plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 GSK plc Recent Developments and Future Plans
2.8 ADC Therapeutics SA
2.8.1 ADC Therapeutics SA Details
2.8.2 ADC Therapeutics SA Major Business
2.8.3 ADC Therapeutics SA Antibody-drug Conjugates Product and Solutions
2.8.4 ADC Therapeutics SA Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 ADC Therapeutics SA Recent Developments and Future Plans
2.9 Takeda Pharmaceutical Company Limited
2.9.1 Takeda Pharmaceutical Company Limited Details
2.9.2 Takeda Pharmaceutical Company Limited Major Business
2.9.3 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product and Solutions
2.9.4 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
2.10 AstraZeneca plc
2.10.1 AstraZeneca plc Details
2.10.2 AstraZeneca plc Major Business
2.10.3 AstraZeneca plc Antibody-drug Conjugates Product and Solutions
2.10.4 AstraZeneca plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 AstraZeneca plc Recent Developments and Future Plans
2.11 Genmab A/S
2.11.1 Genmab A/S Details
2.11.2 Genmab A/S Major Business
2.11.3 Genmab A/S Antibody-drug Conjugates Product and Solutions
2.11.4 Genmab A/S Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Genmab A/S Recent Developments and Future Plans
2.12 Johnson & Johnson
2.12.1 Johnson & Johnson Details
2.12.2 Johnson & Johnson Major Business
2.12.3 Johnson & Johnson Antibody-drug Conjugates Product and Solutions
2.12.4 Johnson & Johnson Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Johnson & Johnson Recent Developments and Future Plans
2.13 Merck & Co., Inc.
2.13.1 Merck & Co., Inc. Details
2.13.2 Merck & Co., Inc. Major Business
2.13.3 Merck & Co., Inc. Antibody-drug Conjugates Product and Solutions
2.13.4 Merck & Co., Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Merck & Co., Inc. Recent Developments and Future Plans
2.14 MacroGenics, Inc.
2.14.1 MacroGenics, Inc. Details
2.14.2 MacroGenics, Inc. Major Business
2.14.3 MacroGenics, Inc. Antibody-drug Conjugates Product and Solutions
2.14.4 MacroGenics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 MacroGenics, Inc. Recent Developments and Future Plans
2.15 Sutro Biopharma, Inc.
2.15.1 Sutro Biopharma, Inc. Details
2.15.2 Sutro Biopharma, Inc. Major Business
2.15.3 Sutro Biopharma, Inc. Antibody-drug Conjugates Product and Solutions
2.15.4 Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Sutro Biopharma, Inc. Recent Developments and Future Plans
2.16 Heidelberg Pharma AG
2.16.1 Heidelberg Pharma AG Details
2.16.2 Heidelberg Pharma AG Major Business
2.16.3 Heidelberg Pharma AG Antibody-drug Conjugates Product and Solutions
2.16.4 Heidelberg Pharma AG Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Heidelberg Pharma AG Recent Developments and Future Plans
2.17 RemeGen Co., Ltd.
2.17.1 RemeGen Co., Ltd. Details
2.17.2 RemeGen Co., Ltd. Major Business
2.17.3 RemeGen Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.17.4 RemeGen Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 RemeGen Co., Ltd. Recent Developments and Future Plans
2.18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2.18.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details
2.18.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
2.18.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.18.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments and Future Plans
2.19 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
2.19.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details
2.19.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
2.19.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.19.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments and Future Plans
2.20 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
2.20.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Details
2.20.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Major Business
2.20.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.20.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments and Future Plans
2.21 Innovent Biologics, Inc.
2.21.1 Innovent Biologics, Inc. Details
2.21.2 Innovent Biologics, Inc. Major Business
2.21.3 Innovent Biologics, Inc. Antibody-drug Conjugates Product and Solutions
2.21.4 Innovent Biologics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 Innovent Biologics, Inc. Recent Developments and Future Plans
2.22 CSPC Pharmaceutical Group Limited
2.22.1 CSPC Pharmaceutical Group Limited Details
2.22.2 CSPC Pharmaceutical Group Limited Major Business
2.22.3 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product and Solutions
2.22.4 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 CSPC Pharmaceutical Group Limited Recent Developments and Future Plans
2.23 Mabwell (Shanghai) Bioscience Co., Ltd.
2.23.1 Mabwell (Shanghai) Bioscience Co., Ltd. Details
2.23.2 Mabwell (Shanghai) Bioscience Co., Ltd. Major Business
2.23.3 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.23.4 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.23.5 Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments and Future Plans
2.24 Lepu Biopharma Co., Ltd.
2.24.1 Lepu Biopharma Co., Ltd. Details
2.24.2 Lepu Biopharma Co., Ltd. Major Business
2.24.3 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.24.4 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.24.5 Lepu Biopharma Co., Ltd. Recent Developments and Future Plans
2.25 Duality Biologics (Shanghai) Co., Ltd.
2.25.1 Duality Biologics (Shanghai) Co., Ltd. Details
2.25.2 Duality Biologics (Shanghai) Co., Ltd. Major Business
2.25.3 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.25.4 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.25.5 Duality Biologics (Shanghai) Co., Ltd. Recent Developments and Future Plans
2.26 MediLink Therapeutics (Suzhou) Co., Ltd.
2.26.1 MediLink Therapeutics (Suzhou) Co., Ltd. Details
2.26.2 MediLink Therapeutics (Suzhou) Co., Ltd. Major Business
2.26.3 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.26.4 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.26.5 MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments and Future Plans
2.27 GeneQuantum Healthcare (Suzhou) Co., Ltd.
2.27.1 GeneQuantum Healthcare (Suzhou) Co., Ltd. Details
2.27.2 GeneQuantum Healthcare (Suzhou) Co., Ltd. Major Business
2.27.3 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.27.4 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.27.5 GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments and Future Plans
2.28 Hangzhou DAC Biotechnology Co., Ltd.
2.28.1 Hangzhou DAC Biotechnology Co., Ltd. Details
2.28.2 Hangzhou DAC Biotechnology Co., Ltd. Major Business
2.28.3 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.28.4 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.28.5 Hangzhou DAC Biotechnology Co., Ltd. Recent Developments and Future Plans
2.29 Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
2.29.1 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Details
2.29.2 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Major Business
2.29.3 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.29.4 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.29.5 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments and Future Plans
2.30 Sichuan Biokin Pharmaceutical Co., Ltd.
2.30.1 Sichuan Biokin Pharmaceutical Co., Ltd. Details
2.30.2 Sichuan Biokin Pharmaceutical Co., Ltd. Major Business
2.30.3 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Solutions
2.30.4 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.30.5 Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments and Future Plans
2.31 Bio-Thera Solutions, Ltd.
2.31.1 Bio-Thera Solutions, Ltd. Details
2.31.2 Bio-Thera Solutions, Ltd. Major Business
2.31.3 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product and Solutions
2.31.4 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.31.5 Bio-Thera Solutions, Ltd. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antibody-drug Conjugates Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Antibody-drug Conjugates by Company Revenue
3.2.2 Top 3 Antibody-drug Conjugates Players Market Share in 2025
3.2.3 Top 6 Antibody-drug Conjugates Players Market Share in 2025
3.3 Antibody-drug Conjugates Market: Overall Company Footprint Analysis
3.3.1 Antibody-drug Conjugates Market: Region Footprint
3.3.2 Antibody-drug Conjugates Market: Company Product Type Footprint
3.3.3 Antibody-drug Conjugates Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Antibody-drug Conjugates Consumption Value and Market Share by Type (2021-2026)
4.2 Global Antibody-drug Conjugates Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2026)
5.2 Global Antibody-drug Conjugates Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Antibody-drug Conjugates Consumption Value by Type (2021-2032)
6.2 North America Antibody-drug Conjugates Market Size by Application (2021-2032)
6.3 North America Antibody-drug Conjugates Market Size by Country
6.3.1 North America Antibody-drug Conjugates Consumption Value by Country (2021-2032)
6.3.2 United States Antibody-drug Conjugates Market Size and Forecast (2021-2032)
6.3.3 Canada Antibody-drug Conjugates Market Size and Forecast (2021-2032)
6.3.4 Mexico Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Antibody-drug Conjugates Consumption Value by Type (2021-2032)
7.2 Europe Antibody-drug Conjugates Consumption Value by Application (2021-2032)
7.3 Europe Antibody-drug Conjugates Market Size by Country
7.3.1 Europe Antibody-drug Conjugates Consumption Value by Country (2021-2032)
7.3.2 Germany Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7.3.3 France Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7.3.5 Russia Antibody-drug Conjugates Market Size and Forecast (2021-2032)
7.3.6 Italy Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Antibody-drug Conjugates Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Antibody-drug Conjugates Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Antibody-drug Conjugates Market Size by Region
8.3.1 Asia-Pacific Antibody-drug Conjugates Consumption Value by Region (2021-2032)
8.3.2 China Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.3 Japan Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.4 South Korea Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.5 India Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Antibody-drug Conjugates Market Size and Forecast (2021-2032)
8.3.7 Australia Antibody-drug Conjugates Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Antibody-drug Conjugates Consumption Value by Type (2021-2032)
9.2 South America Antibody-drug Conjugates Consumption Value by Application (2021-2032)
9.3 South America Antibody-drug Conjugates Market Size by Country
9.3.1 South America Antibody-drug Conjugates Consumption Value by Country (2021-2032)
9.3.2 Brazil Antibody-drug Conjugates Market Size and Forecast (2021-2032)
9.3.3 Argentina Antibody-drug Conjugates Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Antibody-drug Conjugates Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Antibody-drug Conjugates Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Antibody-drug Conjugates Market Size by Country
10.3.1 Middle East & Africa Antibody-drug Conjugates Consumption Value by Country (2021-2032)
10.3.2 Turkey Antibody-drug Conjugates Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Antibody-drug Conjugates Market Size and Forecast (2021-2032)
10.3.4 UAE Antibody-drug Conjugates Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Antibody-drug Conjugates Market Drivers
11.2 Antibody-drug Conjugates Market Restraints
11.3 Antibody-drug Conjugates Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Antibody-drug Conjugates Industry Chain
12.2 Antibody-drug Conjugates Upstream Analysis
12.3 Antibody-drug Conjugates Midstream Analysis
12.4 Antibody-drug Conjugates Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Antibody-drug Conjugates Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Antibody-drug Conjugates Consumption Value by Payload Mechanism, (USD Million), 2021 & 2025 & 2032
Table 3. Global Antibody-drug Conjugates Consumption Value by Drug-To-Antibody Ratio, (USD Million), 2021 & 2025 & 2032
Table 4. Global Antibody-drug Conjugates Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Antibody-drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Antibody-drug Conjugates Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Daiichi Sankyo Company, Limited Company Information, Head Office, and Major Competitors
Table 8. Daiichi Sankyo Company, Limited Major Business
Table 9. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product and Solutions
Table 10. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Daiichi Sankyo Company, Limited Recent Developments and Future Plans
Table 12. Roche Company Information, Head Office, and Major Competitors
Table 13. Roche Major Business
Table 14. Roche Antibody-drug Conjugates Product and Solutions
Table 15. Roche Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Roche Recent Developments and Future Plans
Table 17. Pfizer Inc. Company Information, Head Office, and Major Competitors
Table 18. Pfizer Inc. Major Business
Table 19. Pfizer Inc. Antibody-drug Conjugates Product and Solutions
Table 20. Pfizer Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Gilead Sciences, Inc. Company Information, Head Office, and Major Competitors
Table 22. Gilead Sciences, Inc. Major Business
Table 23. Gilead Sciences, Inc. Antibody-drug Conjugates Product and Solutions
Table 24. Gilead Sciences, Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Gilead Sciences, Inc. Recent Developments and Future Plans
Table 26. Astellas Pharma Inc. Company Information, Head Office, and Major Competitors
Table 27. Astellas Pharma Inc. Major Business
Table 28. Astellas Pharma Inc. Antibody-drug Conjugates Product and Solutions
Table 29. Astellas Pharma Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Astellas Pharma Inc. Recent Developments and Future Plans
Table 31. AbbVie Inc. Company Information, Head Office, and Major Competitors
Table 32. AbbVie Inc. Major Business
Table 33. AbbVie Inc. Antibody-drug Conjugates Product and Solutions
Table 34. AbbVie Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. AbbVie Inc. Recent Developments and Future Plans
Table 36. GSK plc Company Information, Head Office, and Major Competitors
Table 37. GSK plc Major Business
Table 38. GSK plc Antibody-drug Conjugates Product and Solutions
Table 39. GSK plc Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. GSK plc Recent Developments and Future Plans
Table 41. ADC Therapeutics SA Company Information, Head Office, and Major Competitors
Table 42. ADC Therapeutics SA Major Business
Table 43. ADC Therapeutics SA Antibody-drug Conjugates Product and Solutions
Table 44. ADC Therapeutics SA Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. ADC Therapeutics SA Recent Developments and Future Plans
Table 46. Takeda Pharmaceutical Company Limited Company Information, Head Office, and Major Competitors
Table 47. Takeda Pharmaceutical Company Limited Major Business
Table 48. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product and Solutions
Table 49. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
Table 51. AstraZeneca plc Company Information, Head Office, and Major Competitors
Table 52. AstraZeneca plc Major Business
Table 53. AstraZeneca plc Antibody-drug Conjugates Product and Solutions
Table 54. AstraZeneca plc Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. AstraZeneca plc Recent Developments and Future Plans
Table 56. Genmab A/S Company Information, Head Office, and Major Competitors
Table 57. Genmab A/S Major Business
Table 58. Genmab A/S Antibody-drug Conjugates Product and Solutions
Table 59. Genmab A/S Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Genmab A/S Recent Developments and Future Plans
Table 61. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 62. Johnson & Johnson Major Business
Table 63. Johnson & Johnson Antibody-drug Conjugates Product and Solutions
Table 64. Johnson & Johnson Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Johnson & Johnson Recent Developments and Future Plans
Table 66. Merck & Co., Inc. Company Information, Head Office, and Major Competitors
Table 67. Merck & Co., Inc. Major Business
Table 68. Merck & Co., Inc. Antibody-drug Conjugates Product and Solutions
Table 69. Merck & Co., Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Merck & Co., Inc. Recent Developments and Future Plans
Table 71. MacroGenics, Inc. Company Information, Head Office, and Major Competitors
Table 72. MacroGenics, Inc. Major Business
Table 73. MacroGenics, Inc. Antibody-drug Conjugates Product and Solutions
Table 74. MacroGenics, Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. MacroGenics, Inc. Recent Developments and Future Plans
Table 76. Sutro Biopharma, Inc. Company Information, Head Office, and Major Competitors
Table 77. Sutro Biopharma, Inc. Major Business
Table 78. Sutro Biopharma, Inc. Antibody-drug Conjugates Product and Solutions
Table 79. Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Sutro Biopharma, Inc. Recent Developments and Future Plans
Table 81. Heidelberg Pharma AG Company Information, Head Office, and Major Competitors
Table 82. Heidelberg Pharma AG Major Business
Table 83. Heidelberg Pharma AG Antibody-drug Conjugates Product and Solutions
Table 84. Heidelberg Pharma AG Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Heidelberg Pharma AG Recent Developments and Future Plans
Table 86. RemeGen Co., Ltd. Company Information, Head Office, and Major Competitors
Table 87. RemeGen Co., Ltd. Major Business
Table 88. RemeGen Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 89. RemeGen Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. RemeGen Co., Ltd. Recent Developments and Future Plans
Table 91. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 92. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
Table 93. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 94. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 96. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Company Information, Head Office, and Major Competitors
Table 97. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
Table 98. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 99. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 100. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments and Future Plans
Table 101. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Company Information, Head Office, and Major Competitors
Table 102. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Major Business
Table 103. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 104. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 105. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments and Future Plans
Table 106. Innovent Biologics, Inc. Company Information, Head Office, and Major Competitors
Table 107. Innovent Biologics, Inc. Major Business
Table 108. Innovent Biologics, Inc. Antibody-drug Conjugates Product and Solutions
Table 109. Innovent Biologics, Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Innovent Biologics, Inc. Recent Developments and Future Plans
Table 111. CSPC Pharmaceutical Group Limited Company Information, Head Office, and Major Competitors
Table 112. CSPC Pharmaceutical Group Limited Major Business
Table 113. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product and Solutions
Table 114. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. CSPC Pharmaceutical Group Limited Recent Developments and Future Plans
Table 116. Mabwell (Shanghai) Bioscience Co., Ltd. Company Information, Head Office, and Major Competitors
Table 117. Mabwell (Shanghai) Bioscience Co., Ltd. Major Business
Table 118. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 119. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 120. Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments and Future Plans
Table 121. Lepu Biopharma Co., Ltd. Company Information, Head Office, and Major Competitors
Table 122. Lepu Biopharma Co., Ltd. Major Business
Table 123. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 124. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 125. Lepu Biopharma Co., Ltd. Recent Developments and Future Plans
Table 126. Duality Biologics (Shanghai) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 127. Duality Biologics (Shanghai) Co., Ltd. Major Business
Table 128. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 129. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 130. Duality Biologics (Shanghai) Co., Ltd. Recent Developments and Future Plans
Table 131. MediLink Therapeutics (Suzhou) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 132. MediLink Therapeutics (Suzhou) Co., Ltd. Major Business
Table 133. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 134. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 135. MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments and Future Plans
Table 136. GeneQuantum Healthcare (Suzhou) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 137. GeneQuantum Healthcare (Suzhou) Co., Ltd. Major Business
Table 138. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 139. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 140. GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments and Future Plans
Table 141. Hangzhou DAC Biotechnology Co., Ltd. Company Information, Head Office, and Major Competitors
Table 142. Hangzhou DAC Biotechnology Co., Ltd. Major Business
Table 143. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 144. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Hangzhou DAC Biotechnology Co., Ltd. Recent Developments and Future Plans
Table 146. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 147. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Major Business
Table 148. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 149. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 150. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments and Future Plans
Table 151. Sichuan Biokin Pharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 152. Sichuan Biokin Pharmaceutical Co., Ltd. Major Business
Table 153. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 154. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 155. Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 156. Bio-Thera Solutions, Ltd. Company Information, Head Office, and Major Competitors
Table 157. Bio-Thera Solutions, Ltd. Major Business
Table 158. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product and Solutions
Table 159. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 160. Bio-Thera Solutions, Ltd. Recent Developments and Future Plans
Table 161. Global Antibody-drug Conjugates Revenue (USD Million) by Players (2021-2026)
Table 162. Global Antibody-drug Conjugates Revenue Share by Players (2021-2026)
Table 163. Breakdown of Antibody-drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3)
Table 164. Market Position of Players in Antibody-drug Conjugates, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 165. Head Office of Key Antibody-drug Conjugates Players
Table 166. Antibody-drug Conjugates Market: Company Product Type Footprint
Table 167. Antibody-drug Conjugates Market: Company Product Application Footprint
Table 168. Antibody-drug Conjugates New Market Entrants and Barriers to Market Entry
Table 169. Antibody-drug Conjugates Mergers, Acquisition, Agreements, and Collaborations
Table 170. Global Antibody-drug Conjugates Consumption Value (USD Million) by Type (2021-2026)
Table 171. Global Antibody-drug Conjugates Consumption Value Share by Type (2021-2026)
Table 172. Global Antibody-drug Conjugates Consumption Value Forecast by Type (2027-2032)
Table 173. Global Antibody-drug Conjugates Consumption Value by Application (2021-2026)
Table 174. Global Antibody-drug Conjugates Consumption Value Forecast by Application (2027-2032)
Table 175. North America Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 176. North America Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 177. North America Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 178. North America Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 179. North America Antibody-drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 180. North America Antibody-drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 181. Europe Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 182. Europe Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 183. Europe Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 184. Europe Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 185. Europe Antibody-drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 186. Europe Antibody-drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 187. Asia-Pacific Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 188. Asia-Pacific Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 189. Asia-Pacific Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 190. Asia-Pacific Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 191. Asia-Pacific Antibody-drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 192. Asia-Pacific Antibody-drug Conjugates Consumption Value by Region (2027-2032) & (USD Million)
Table 193. South America Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 194. South America Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 195. South America Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 196. South America Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 197. South America Antibody-drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 198. South America Antibody-drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 199. Middle East & Africa Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 200. Middle East & Africa Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 201. Middle East & Africa Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 202. Middle East & Africa Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 203. Middle East & Africa Antibody-drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 204. Middle East & Africa Antibody-drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 205. Global Key Players of Antibody-drug Conjugates Upstream (Raw Materials)
Table 206. Global Antibody-drug Conjugates Typical Customers
Table 1. Global Antibody-drug Conjugates Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Antibody-drug Conjugates Consumption Value by Payload Mechanism, (USD Million), 2021 & 2025 & 2032
Table 3. Global Antibody-drug Conjugates Consumption Value by Drug-To-Antibody Ratio, (USD Million), 2021 & 2025 & 2032
Table 4. Global Antibody-drug Conjugates Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Antibody-drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Antibody-drug Conjugates Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Daiichi Sankyo Company, Limited Company Information, Head Office, and Major Competitors
Table 8. Daiichi Sankyo Company, Limited Major Business
Table 9. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product and Solutions
Table 10. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Daiichi Sankyo Company, Limited Recent Developments and Future Plans
Table 12. Roche Company Information, Head Office, and Major Competitors
Table 13. Roche Major Business
Table 14. Roche Antibody-drug Conjugates Product and Solutions
Table 15. Roche Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Roche Recent Developments and Future Plans
Table 17. Pfizer Inc. Company Information, Head Office, and Major Competitors
Table 18. Pfizer Inc. Major Business
Table 19. Pfizer Inc. Antibody-drug Conjugates Product and Solutions
Table 20. Pfizer Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Gilead Sciences, Inc. Company Information, Head Office, and Major Competitors
Table 22. Gilead Sciences, Inc. Major Business
Table 23. Gilead Sciences, Inc. Antibody-drug Conjugates Product and Solutions
Table 24. Gilead Sciences, Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Gilead Sciences, Inc. Recent Developments and Future Plans
Table 26. Astellas Pharma Inc. Company Information, Head Office, and Major Competitors
Table 27. Astellas Pharma Inc. Major Business
Table 28. Astellas Pharma Inc. Antibody-drug Conjugates Product and Solutions
Table 29. Astellas Pharma Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Astellas Pharma Inc. Recent Developments and Future Plans
Table 31. AbbVie Inc. Company Information, Head Office, and Major Competitors
Table 32. AbbVie Inc. Major Business
Table 33. AbbVie Inc. Antibody-drug Conjugates Product and Solutions
Table 34. AbbVie Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. AbbVie Inc. Recent Developments and Future Plans
Table 36. GSK plc Company Information, Head Office, and Major Competitors
Table 37. GSK plc Major Business
Table 38. GSK plc Antibody-drug Conjugates Product and Solutions
Table 39. GSK plc Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. GSK plc Recent Developments and Future Plans
Table 41. ADC Therapeutics SA Company Information, Head Office, and Major Competitors
Table 42. ADC Therapeutics SA Major Business
Table 43. ADC Therapeutics SA Antibody-drug Conjugates Product and Solutions
Table 44. ADC Therapeutics SA Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. ADC Therapeutics SA Recent Developments and Future Plans
Table 46. Takeda Pharmaceutical Company Limited Company Information, Head Office, and Major Competitors
Table 47. Takeda Pharmaceutical Company Limited Major Business
Table 48. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product and Solutions
Table 49. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
Table 51. AstraZeneca plc Company Information, Head Office, and Major Competitors
Table 52. AstraZeneca plc Major Business
Table 53. AstraZeneca plc Antibody-drug Conjugates Product and Solutions
Table 54. AstraZeneca plc Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. AstraZeneca plc Recent Developments and Future Plans
Table 56. Genmab A/S Company Information, Head Office, and Major Competitors
Table 57. Genmab A/S Major Business
Table 58. Genmab A/S Antibody-drug Conjugates Product and Solutions
Table 59. Genmab A/S Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Genmab A/S Recent Developments and Future Plans
Table 61. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 62. Johnson & Johnson Major Business
Table 63. Johnson & Johnson Antibody-drug Conjugates Product and Solutions
Table 64. Johnson & Johnson Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Johnson & Johnson Recent Developments and Future Plans
Table 66. Merck & Co., Inc. Company Information, Head Office, and Major Competitors
Table 67. Merck & Co., Inc. Major Business
Table 68. Merck & Co., Inc. Antibody-drug Conjugates Product and Solutions
Table 69. Merck & Co., Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Merck & Co., Inc. Recent Developments and Future Plans
Table 71. MacroGenics, Inc. Company Information, Head Office, and Major Competitors
Table 72. MacroGenics, Inc. Major Business
Table 73. MacroGenics, Inc. Antibody-drug Conjugates Product and Solutions
Table 74. MacroGenics, Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. MacroGenics, Inc. Recent Developments and Future Plans
Table 76. Sutro Biopharma, Inc. Company Information, Head Office, and Major Competitors
Table 77. Sutro Biopharma, Inc. Major Business
Table 78. Sutro Biopharma, Inc. Antibody-drug Conjugates Product and Solutions
Table 79. Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Sutro Biopharma, Inc. Recent Developments and Future Plans
Table 81. Heidelberg Pharma AG Company Information, Head Office, and Major Competitors
Table 82. Heidelberg Pharma AG Major Business
Table 83. Heidelberg Pharma AG Antibody-drug Conjugates Product and Solutions
Table 84. Heidelberg Pharma AG Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Heidelberg Pharma AG Recent Developments and Future Plans
Table 86. RemeGen Co., Ltd. Company Information, Head Office, and Major Competitors
Table 87. RemeGen Co., Ltd. Major Business
Table 88. RemeGen Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 89. RemeGen Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. RemeGen Co., Ltd. Recent Developments and Future Plans
Table 91. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 92. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
Table 93. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 94. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 96. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Company Information, Head Office, and Major Competitors
Table 97. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
Table 98. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 99. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 100. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments and Future Plans
Table 101. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Company Information, Head Office, and Major Competitors
Table 102. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Major Business
Table 103. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 104. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 105. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments and Future Plans
Table 106. Innovent Biologics, Inc. Company Information, Head Office, and Major Competitors
Table 107. Innovent Biologics, Inc. Major Business
Table 108. Innovent Biologics, Inc. Antibody-drug Conjugates Product and Solutions
Table 109. Innovent Biologics, Inc. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Innovent Biologics, Inc. Recent Developments and Future Plans
Table 111. CSPC Pharmaceutical Group Limited Company Information, Head Office, and Major Competitors
Table 112. CSPC Pharmaceutical Group Limited Major Business
Table 113. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product and Solutions
Table 114. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. CSPC Pharmaceutical Group Limited Recent Developments and Future Plans
Table 116. Mabwell (Shanghai) Bioscience Co., Ltd. Company Information, Head Office, and Major Competitors
Table 117. Mabwell (Shanghai) Bioscience Co., Ltd. Major Business
Table 118. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 119. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 120. Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments and Future Plans
Table 121. Lepu Biopharma Co., Ltd. Company Information, Head Office, and Major Competitors
Table 122. Lepu Biopharma Co., Ltd. Major Business
Table 123. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 124. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 125. Lepu Biopharma Co., Ltd. Recent Developments and Future Plans
Table 126. Duality Biologics (Shanghai) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 127. Duality Biologics (Shanghai) Co., Ltd. Major Business
Table 128. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 129. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 130. Duality Biologics (Shanghai) Co., Ltd. Recent Developments and Future Plans
Table 131. MediLink Therapeutics (Suzhou) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 132. MediLink Therapeutics (Suzhou) Co., Ltd. Major Business
Table 133. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 134. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 135. MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments and Future Plans
Table 136. GeneQuantum Healthcare (Suzhou) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 137. GeneQuantum Healthcare (Suzhou) Co., Ltd. Major Business
Table 138. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 139. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 140. GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments and Future Plans
Table 141. Hangzhou DAC Biotechnology Co., Ltd. Company Information, Head Office, and Major Competitors
Table 142. Hangzhou DAC Biotechnology Co., Ltd. Major Business
Table 143. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 144. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Hangzhou DAC Biotechnology Co., Ltd. Recent Developments and Future Plans
Table 146. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 147. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Major Business
Table 148. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 149. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 150. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments and Future Plans
Table 151. Sichuan Biokin Pharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 152. Sichuan Biokin Pharmaceutical Co., Ltd. Major Business
Table 153. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Solutions
Table 154. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 155. Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 156. Bio-Thera Solutions, Ltd. Company Information, Head Office, and Major Competitors
Table 157. Bio-Thera Solutions, Ltd. Major Business
Table 158. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product and Solutions
Table 159. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 160. Bio-Thera Solutions, Ltd. Recent Developments and Future Plans
Table 161. Global Antibody-drug Conjugates Revenue (USD Million) by Players (2021-2026)
Table 162. Global Antibody-drug Conjugates Revenue Share by Players (2021-2026)
Table 163. Breakdown of Antibody-drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3)
Table 164. Market Position of Players in Antibody-drug Conjugates, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 165. Head Office of Key Antibody-drug Conjugates Players
Table 166. Antibody-drug Conjugates Market: Company Product Type Footprint
Table 167. Antibody-drug Conjugates Market: Company Product Application Footprint
Table 168. Antibody-drug Conjugates New Market Entrants and Barriers to Market Entry
Table 169. Antibody-drug Conjugates Mergers, Acquisition, Agreements, and Collaborations
Table 170. Global Antibody-drug Conjugates Consumption Value (USD Million) by Type (2021-2026)
Table 171. Global Antibody-drug Conjugates Consumption Value Share by Type (2021-2026)
Table 172. Global Antibody-drug Conjugates Consumption Value Forecast by Type (2027-2032)
Table 173. Global Antibody-drug Conjugates Consumption Value by Application (2021-2026)
Table 174. Global Antibody-drug Conjugates Consumption Value Forecast by Application (2027-2032)
Table 175. North America Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 176. North America Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 177. North America Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 178. North America Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 179. North America Antibody-drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 180. North America Antibody-drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 181. Europe Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 182. Europe Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 183. Europe Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 184. Europe Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 185. Europe Antibody-drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 186. Europe Antibody-drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 187. Asia-Pacific Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 188. Asia-Pacific Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 189. Asia-Pacific Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 190. Asia-Pacific Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 191. Asia-Pacific Antibody-drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 192. Asia-Pacific Antibody-drug Conjugates Consumption Value by Region (2027-2032) & (USD Million)
Table 193. South America Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 194. South America Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 195. South America Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 196. South America Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 197. South America Antibody-drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 198. South America Antibody-drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 199. Middle East & Africa Antibody-drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 200. Middle East & Africa Antibody-drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 201. Middle East & Africa Antibody-drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 202. Middle East & Africa Antibody-drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 203. Middle East & Africa Antibody-drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 204. Middle East & Africa Antibody-drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 205. Global Key Players of Antibody-drug Conjugates Upstream (Raw Materials)
Table 206. Global Antibody-drug Conjugates Typical Customers
LIST OF FIGURES
Figure 1. Antibody-drug Conjugates Picture
Figure 2. Global Antibody-drug Conjugates Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Antibody-drug Conjugates Consumption Value Market Share by Type in 2025
Figure 4. HER2-Directed ADCs
Figure 5. TROP2-Directed ADCs
Figure 6. Hematologic-Lineage Antigen ADCs
Figure 7. Other Target Antigen ADCs
Figure 8. Global Antibody-drug Conjugates Consumption Value by Payload Mechanism, (USD Million), 2021 & 2025 & 2032
Figure 9. Global Antibody-drug Conjugates Consumption Value Market Share by Payload Mechanism in 2025
Figure 10. Topoisomerase I Inhibitor ADCs
Figure 11. Microtubule Inhibitor ADCs
Figure 12. DNA-Damaging ADCs
Figure 13. Other Payload ADCs
Figure 14. Global Antibody-drug Conjugates Consumption Value by Drug-To-Antibody Ratio, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Antibody-drug Conjugates Consumption Value Market Share by Drug-To-Antibody Ratio in 2025
Figure 16. DAR Up To 4
Figure 17. DAR Above 4 And Below 8
Figure 18. DAR 8 And Above
Figure 19. Other
Figure 20. Global Antibody-drug Conjugates Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 21. Antibody-drug Conjugates Consumption Value Market Share by Application in 2025
Figure 22. Breast and Gynecologic Malignancies Picture
Figure 23. Lung and Other Thoracic Malignancies Picture
Figure 24. Other Solid Tumors Picture
Figure 25. Hematologic Malignancies Picture
Figure 26. Global Antibody-drug Conjugates Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 27. Global Antibody-drug Conjugates Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 28. Global Market Antibody-drug Conjugates Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 29. Global Antibody-drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 30. Global Antibody-drug Conjugates Consumption Value Market Share by Region in 2025
Figure 31. North America Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 32. Europe Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 33. Asia-Pacific Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 34. South America Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 35. Middle East & Africa Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 36. Company Three Recent Developments and Future Plans
Figure 37. Global Antibody-drug Conjugates Revenue Share by Players in 2025
Figure 38. Antibody-drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 39. Market Share of Antibody-drug Conjugates by Player Revenue in 2025
Figure 40. Top 3 Antibody-drug Conjugates Players Market Share in 2025
Figure 41. Top 6 Antibody-drug Conjugates Players Market Share in 2025
Figure 42. Global Antibody-drug Conjugates Consumption Value Share by Type (2021-2026)
Figure 43. Global Antibody-drug Conjugates Market Share Forecast by Type (2027-2032)
Figure 44. Global Antibody-drug Conjugates Consumption Value Share by Application (2021-2026)
Figure 45. Global Antibody-drug Conjugates Market Share Forecast by Application (2027-2032)
Figure 46. North America Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 47. North America Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 48. North America Antibody-drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 49. United States Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 50. Canada Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 51. Mexico Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 52. Europe Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 53. Europe Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 54. Europe Antibody-drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 55. Germany Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 56. France Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 57. United Kingdom Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 58. Russia Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 59. Italy Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 60. Asia-Pacific Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 61. Asia-Pacific Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 62. Asia-Pacific Antibody-drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 63. China Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 64. Japan Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 65. South Korea Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 66. India Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 67. Southeast Asia Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 68. Australia Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 69. South America Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 70. South America Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 71. South America Antibody-drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 72. Brazil Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 73. Argentina Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 74. Middle East & Africa Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 75. Middle East & Africa Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 76. Middle East & Africa Antibody-drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 77. Turkey Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 78. Saudi Arabia Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 79. UAE Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 80. Antibody-drug Conjugates Market Drivers
Figure 81. Antibody-drug Conjugates Market Restraints
Figure 82. Antibody-drug Conjugates Market Trends
Figure 83. Porters Five Forces Analysis
Figure 84. Antibody-drug Conjugates Industrial Chain
Figure 85. Methodology
Figure 86. Research Process and Data Source
Figure 1. Antibody-drug Conjugates Picture
Figure 2. Global Antibody-drug Conjugates Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Antibody-drug Conjugates Consumption Value Market Share by Type in 2025
Figure 4. HER2-Directed ADCs
Figure 5. TROP2-Directed ADCs
Figure 6. Hematologic-Lineage Antigen ADCs
Figure 7. Other Target Antigen ADCs
Figure 8. Global Antibody-drug Conjugates Consumption Value by Payload Mechanism, (USD Million), 2021 & 2025 & 2032
Figure 9. Global Antibody-drug Conjugates Consumption Value Market Share by Payload Mechanism in 2025
Figure 10. Topoisomerase I Inhibitor ADCs
Figure 11. Microtubule Inhibitor ADCs
Figure 12. DNA-Damaging ADCs
Figure 13. Other Payload ADCs
Figure 14. Global Antibody-drug Conjugates Consumption Value by Drug-To-Antibody Ratio, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Antibody-drug Conjugates Consumption Value Market Share by Drug-To-Antibody Ratio in 2025
Figure 16. DAR Up To 4
Figure 17. DAR Above 4 And Below 8
Figure 18. DAR 8 And Above
Figure 19. Other
Figure 20. Global Antibody-drug Conjugates Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 21. Antibody-drug Conjugates Consumption Value Market Share by Application in 2025
Figure 22. Breast and Gynecologic Malignancies Picture
Figure 23. Lung and Other Thoracic Malignancies Picture
Figure 24. Other Solid Tumors Picture
Figure 25. Hematologic Malignancies Picture
Figure 26. Global Antibody-drug Conjugates Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 27. Global Antibody-drug Conjugates Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 28. Global Market Antibody-drug Conjugates Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 29. Global Antibody-drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 30. Global Antibody-drug Conjugates Consumption Value Market Share by Region in 2025
Figure 31. North America Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 32. Europe Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 33. Asia-Pacific Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 34. South America Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 35. Middle East & Africa Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 36. Company Three Recent Developments and Future Plans
Figure 37. Global Antibody-drug Conjugates Revenue Share by Players in 2025
Figure 38. Antibody-drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 39. Market Share of Antibody-drug Conjugates by Player Revenue in 2025
Figure 40. Top 3 Antibody-drug Conjugates Players Market Share in 2025
Figure 41. Top 6 Antibody-drug Conjugates Players Market Share in 2025
Figure 42. Global Antibody-drug Conjugates Consumption Value Share by Type (2021-2026)
Figure 43. Global Antibody-drug Conjugates Market Share Forecast by Type (2027-2032)
Figure 44. Global Antibody-drug Conjugates Consumption Value Share by Application (2021-2026)
Figure 45. Global Antibody-drug Conjugates Market Share Forecast by Application (2027-2032)
Figure 46. North America Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 47. North America Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 48. North America Antibody-drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 49. United States Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 50. Canada Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 51. Mexico Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 52. Europe Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 53. Europe Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 54. Europe Antibody-drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 55. Germany Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 56. France Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 57. United Kingdom Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 58. Russia Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 59. Italy Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 60. Asia-Pacific Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 61. Asia-Pacific Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 62. Asia-Pacific Antibody-drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 63. China Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 64. Japan Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 65. South Korea Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 66. India Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 67. Southeast Asia Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 68. Australia Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 69. South America Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 70. South America Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 71. South America Antibody-drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 72. Brazil Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 73. Argentina Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 74. Middle East & Africa Antibody-drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 75. Middle East & Africa Antibody-drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 76. Middle East & Africa Antibody-drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 77. Turkey Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 78. Saudi Arabia Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 79. UAE Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 80. Antibody-drug Conjugates Market Drivers
Figure 81. Antibody-drug Conjugates Market Restraints
Figure 82. Antibody-drug Conjugates Market Trends
Figure 83. Porters Five Forces Analysis
Figure 84. Antibody-drug Conjugates Industrial Chain
Figure 85. Methodology
Figure 86. Research Process and Data Source
More Publications
Global Anticancer Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031
US$ 3,480.00
June 2025
127 pages
Global Cancer Monoclonal Antibodies Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
US$ 3,480.00
July 2024
72 pages
Global Antibody Supply, Demand and Key Producers, 2026-2032
US$ 4,480.00
January 2026
146 pages
Global Procalcitonin Antibody Supply, Demand and Key Producers, 2026-2032
US$ 4,480.00
January 2026
135 pages
Global IGY Polyclonal Antibodies Supply, Demand and Key Producers, 2026-2032
US$ 4,480.00
January 2026
111 pages
